facebook button KRYSTAL-10: Adagrasib in KRAS G12C Mutated Colorectal Cancer Protocol 849-010
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

KRYSTAL-10: Adagrasib in KRAS G12C Mutated Colorectal Cancer

Sponsor: Mirati Therapeutics, Inc.

Protocol 849-010: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Eligible patients will have a colon or rectal carcinoma with a KRAS G12C mutation and have a history of treatment with a fluoropyrimidine-based chemotherapy regimen including either irinotecan or oxaliplatin.

For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly at 631-675-5075.